Visirna Therapeutics

China
Shaxi, Fujian, China

Company profile

Visirna Therapeutics company profile

Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.

Business identity

Contact email
[email protected]
Phone number
+86 021-6107 5030
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Founded
2022-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$60M
Last funding
Seed / $60M / 2022-04-25
Last equity funding
Seed / $60M
Investors
1
Lead investors
1
Articles
15

Founders and investors

Lead investors

Vivo Capital

Investors

Vivo Capital